Seeing Machines Regulatory News (SEE)

9 Nov 2006 07:01

Seeing Machines Limited09 November 2006 9th November 2006 Seeing Machines Limited ("Seeing Machines" or the "Company") GLAUCOMA CLINICAL STUDY RE-COMMENCES Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, announces today the commencement of the next phase ofthe second clinical study (CT2b) for its glaucoma testing device, Truefield, asforeshadowed in the announcement of 30 August 2006 headed 'Glaucoma ProjectClinical Study Results'. CT2b will commence on 20 November 2006 and willinvolve 160 patients in a clinical setting at the Canberra Eye Hospital,Australia. The commencement of this phase of the study follows the successful completion oftwo scientific studies T13 and T14 at the Canberra Eye Hospital in Septemberand October. These studies confirmed the results of the earlier CT1 study whichshowed that the device: • successfully detects the loss of visual field associated with glaucoma; and • successfully differentiates between those patients with visual field loss and those without, thus providing the basis for a reliable and accurate diagnostic instrument. The two scientific studies also highlighted that the expected improvements inthe performance of the technology since the CT1 study had been achieved. Commenting on the scientific study results Nick Cerneaz, CEO of Seeing Machinessaid: "These results are very positive and enable us to move forward with ourplans for the introduction of the device, firstly with the commencement of thenext phase of the clinical study, but also all of the other activities needed tobring the device to market. This device, TrueField, will be the world's firstnon-contact objective test for glaucoma, testing both eyes in 4 minutes. Theseare very significant advantages over existing glaucoma diagnostic devices on themarket today and we have every reason to be confident about the ultimatecommercial success of TrueField. Our aim, which we are pursuing aggressively,is to launch the device during calendar year 2007. We are very grateful for thework of our partners at the Australian National University led by Dr Ted Maddessand Dr Andrew James and the support we receive from the Canberra Eye Hospital.I would also like to acknowledge the work of our own very dedicated staff andalso the financial support we receive for the project from the AustralianGovernment's Commercial Ready Program". --- ENDS --- Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange